Sonata Therapeutics
Michael Crescenzi has a vast experience in strategy, operations, and corporate development within the pharmaceutical industry. Michael has held various leadership positions in companies such as Sonata Therapeutics, Selenity Therapeutics, Viamet Pharmaceuticals, Talecris Biotherapeutics/Grifols, GlaxoSmithKline, and more. With a background in Biology and an MBA in Marketing and Finance, Michael has successfully led global marketing teams, developed go-to-market strategies, and played key roles in business development and exit strategies for various companies.
Sonata Therapeutics
Sonata Therapeutics is a new, Boston-based Flagship Pioneering company revolutionizing the world’s understanding of the cellular microenvironment and its importance to human biology and disease. Our product-platform creates drugs based on a systematic, comprehensive characterization of the microenvironment in diseases with high unmet medical need. Through our pioneering science, we identify new targets for therapeutics that induce the release of a programmed diversity of signals with the potential for significant patient impact. Our employees are exceptionally passionate, accountable, collaborative, and innovative. Sonata Therapeutics was founded by Flagship Pioneering, an organization dedicated to the origination and development of first-in-category life sciences companies. Since 2000, Flagship has originated and fostered the development of nearly 100 scientific ventures resulting in $20+ billion in aggregate value, 500+ issued patents, and more than 50 clinical trials for novel therapeutic agents.